FDA | Sensor "Compliance" Pill Approved | Nov 2017

2 years ago
279

November 2017

Abilify MyCite contains a Boxed Warning with an increased risk of death.

The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants.

In the clinical trials for Abilify, the most common side effects reported by adults taking Abilify were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness.

I HOPE YOU DIDNT MISS THAT...

"uncontrollable limb and body movements (akathisia)"

WAS LISTED AMONGST THE MOST COMMON SIDE EFFECTS IN THE CLINICAL TRIALS.

"The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012."

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
https://www.fda.gov/news-events/press-announcements/fda-approves-pill-sensor-digitally-tracks-if-patients-have-ingested-their-medication

Archive Copy:
https://archive.ph/RbWaT

Download on Telegram: https://t.me/c19Videos/238
https://t.me/c19Videos/239

Link to FDA Files:
https://t.me/c19Videos/237

This Video Clip:
https://t.me/c19Videos/238

Screenshots & PDF Copy of FDA Blackbox warnings
https://t.me/c19Videos/239

Loading 4 comments...